anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
APLENZIN can cause seizure. The risk of seizure is dose-related. The dose should not exceed 522 mg once daily. Increase the dose gradually. Discontinue APLENZIN and do not restart treatment if the patient experiences a seizure.

The risk of seizures is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold. Consider these risks before initiating treatment with APLENZIN. APLENZIN is contraindicated in patients with a seizure disorder or conditions that increase the risk of seizure (e.g., severe head injury, arteriovenous malformation, CNS tumor or CNS infection, severe stroke, anorexia nervosa or bulimia, or abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Contraindications (4)]. The following conditions can also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse of prescription drugs such as CNS stimulants. Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates.

Incidence of Seizure with Bupropion Use

The incidence of seizure with APLENZIN has not been formally evaluated in clinical trials. In studies using bupropion HCl sustained-release up to 300 mg per day (equivalent to APLENZIN 348 mg per day) the incidence of seizure was approximately 0.1% (1/1,000 patients). In a large prospective, follow-up study, the seizure incidence was approximately 0.4% (13/3,200) with bupropion HCl immediate-release in the range of 300 mg to 450 mg per day (equivalent to APLENZIN 348 mg to 522 mg per day).

Additional data accumulated for bupropion immediate-release suggests that the estimated seizure incidence increases almost tenfold between 450 and 600 mg/day (equivalent to APLENZIN 522 mg and 696 mg per day). The risk of seizure can be reduced if the APLENZIN dose does not exceed 522 mg once daily and the titration rate is gradual.
The invention provides a pyrimidoindole compound, a preparation method and application thereof, and an anti-erythroleukemia drug, belonging to the technical field of organic compounds. The UM171 derivative provided by the invention has better anti-erythroleukemia activity, and has more remarkable effect on erythroleukemia cells (HEL and CB 3), wherein the UM171-9 has more remarkable effect on erythroleukemia. In erythroleukemia HEL cells, UM171-9 induced apoptosis and blocked the cell in the G2 phase. UM171-9 upregulates mRNA expression of the cyclin P21 and the tumor suppressor KLF 2. In addition, UM171-9 prolongs the survival time of erythroleukemia mice, increases the blood volume ratio, reduces the spleen weight of mice, and exerts anti-erythroleukemia activity. UM171-9 can be used as potential small molecule medicine for treating erythroleukemia, and provides research basis for treating erythroleukemia.
Tremor is a prevalent neurological disorder characterized by involuntary shaking or trembling of body parts. This condition impairs fine motor skills and hand coordination to varying degrees and can even affect overall body mobility. As a result, tremors severely disrupt the daily lives and work of those affected, significantly limiting their physical activity space. This study developed an innovative spatial augmented reality (SAR) system aimed at assisting individuals with tremor disorders to overcome their physical limitations and expand their range of activities. The system integrates eye-tracking and Internet of Things (IoT) technologies, enabling users to smoothly control objects in the real world through eye movements. It uses a virtual stabilization algorithm for stable interaction with objects in the real environment. The study comprehensively evaluated the system's performance through three experiments: (1) assessing the effectiveness of the virtual stabilization algorithm in enhancing the system's ability to assist individuals with tremors in stable and efficient interaction with remote objects, (2) evaluating the system's fluidity and stability in performing complex interactive tasks, and (3) investigating the precision and efficiency of the system in remote interactions within complex physical environments. The results demonstrated that the system significantly improves the stability and efficiency of interactions between individuals with tremor and remote objects, reduces operational errors, and enhances the accuracy and communication efficiency of interactions.
Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
PROBLEM TO BE SOLVED: To obtain a composition for aromatizing capable of manifesting stable aromaticity in a chlorinated medium and even in a medium manifesting a high pH value by adding a specific methoxymethylphenylpropane, methoxypropylmethylbenzene or methoxytrimethylphenylbutane to the composition for aromatizing. SOLUTION: (A) 1-Methoxy-2-methyl-3-phenylpropane, (B) 1-(2- methoxypropyl)-4-methylbenzene or (C) 3-methoxy-2,2,3-trimethyl-1-phenylbutane is added to a composition for aromatizing. The ingredient is capable of manifesting excellent stability especially in a chlorine bleaching agent and effectively covering a typical, offensive and smothering odor of a chlorine bleaching agent. In the composition, the ratio at which the ingredients can homogeneously be mixed is, e.g. about 0.1-10 wt.%. The ingredients B and C are new compounds.
1,236,709. Softening composition. M. BIERRE. 30 July, 1969 [2 Aug., 1968], No. 38357/ 69. Heading ASB. [Also in Division C5] A softening composition comprises (1) a salt of an organic acid with the amino group of a natural or synthetic amino acid, and (2) a salt of a sulphite, bisulphite, hydrosulphite or hyposulphite with the amino group of a natural or synthetic amino acid, in which the organic acid is cyclic or non-cyclic and contains up to 24 carbon atoms per molecule, the natural or synthetic amino acid contains from 1-12 carbon atoms per molecule, and when the amino acid is a mono acid the organic acid is a diacid or polyacid and when the amino acid is a diacid the organic acid is a mono acid or poly acid. The amino acid may be an extract of a protein substance such as collagen or keratin. The composition may also comprise a sequestering agent, an antioxidant, a preservative, a milk, a beauty cream, an alcohol, a perfume or a dye. Examples are given of compositions for shampoos, dentifrices, beauty creams and after shave lotions.
Structural racism and discrimination (SRD) are complex and drive racial inequities. SRD has sustained racial health disparities in the United States, driven disproportionate incarceration risk among Black men, and systematically restricted minority populations from health, wealth, and prosperity. As a result, diminished income earning ability for generations of Black people has led to economic devastation and poor health. Importantly, older and aging Black men continue to earn less than their White counterparts and the income gap is continuing to widen. Even when accounting for education, research has shown that the rising wage gap is attributable to workforce experience and opportunity, hiring and wage discrimination, and incarceration. Difficulty attaining prevailing wages among older Black men affects family stability, the ability for communities to thrive, and population health. Geography, place, and proximity to capital and markets are underlying drivers of health behavior and healthcare access. As a result, older and aging Black men in particular have demonstrated one of the strongest epidemiologic relationships between low socioeconomic status, residence in communities with endemic poverty, and chronic disease. The proposed Stage 3 efficacy study aims to test a novel intervention that directly reduces the racial income gap by providing a universal basic income (UBI). UBI is intended to promote and protect Black men's health through the influx of capital and subsequent increases in personal agency and social connections. We hypothesize that providing UBI of $500 per month for six months will result in increased healthcare utilization among chronically-ill, older and aging, low-income Black men. Secondarily, we hypothesize that the effect of UBI will depend on whether an individual has a recent history of incarceration, such that no incarceration history combined with UBI ill demonstrate the best study outcomes.

Empirical research examining UBI among older Black men and its capacity to overturn SRD are lacking in the extant literature. Much of the health disparities research intended to inform health and economic policy originated from limited perspectives of older and aging Black men. Dr. W.E.B. Du Bois said in The Souls of Black Folk that for Black people, "discouragement is an unwritten word". This study draws on that inspiration as it ultimately seeks to fundamentally overturn the economic oppression and brutality that has defined the Black experience for generations.
A system is disclosed that includes an optical tracking device and a surgical computing device. The optical tracking device includes a structured light module and an optical module including an image sensor and spaced apart from the structured light module by a known distance. The surgical computing device includes a display device, a non-transitory computer-readable medium comprising instructions, and a processor configured to execute the instructions to generate a depth map from a first image captured by the image sensor during projection of a pattern into a surgical environment by the structured light module. The pattern is projected in the Near Infrared (NIR) spectrum. The processor is further configured to execute the stored instructions to reconstruct a 3D surface of the anatomical structure based on the generated depth map. Additionally, the processor is configured to execute the stored instructions to output the reconstructed 3D surface to the display device.
Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
A total of 150 subjects in this group received abiraterone acetate + prednisolone acetate daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
A single case experimental design (SCED) with AB and follow-up phases across participants will be used. Within this study design, every participant will receive the blended eHealth cognitive behavioral (group)intervention (e-COGRAT). Patients who have given consent to participate in the study will be assigned to a treatment group by random assignment. Each group consists of 4 participants. Due to the group-based intervention all participants of each group will start simultaneously and immediately after baseline phase (2 weeks) with the 12-week intervention phase. Start dates will be predetermined based on the running dates of each group. The follow-up phase, immediately following after intervention phase, will take 24 weeks. The total duration of the study is 37 weeks.
This prospective randomized controlled study included 108 women with unexplained infertility recruited among those attending the Gynecology Outpatient Clinics of, Benha University Hospital, and private settings, Alkalubia, Egypt from Jun 2013 to Aug 2015. The study protocol was approved by the Local Ethics Committee and written informed consents were taken from both partners before starting of the study.

All women received the same regimen of ovarian stimulation using Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5 mg tab twice daily for 5 days starting from cycle day 3. Transvaginal ultrasound scan (TVS) was performed daily from cycle day 9 and a total of 10,000 IU of hCG (Epifasi, EPICO) was administered to those in whom at least one ovarian follicle was ≥18 mm in size. On the day of hCG administration women were randomly categorized into two groups according to a computer generated random numerical table. Envelopes containing the allocation information were chosen sequentially by patient herself in presence of her husband. Group A received FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once on day of hCG injection and group B received no FSH on day of hCG injection. Intrauterine insemination was performed 36 hours after HCG injection. Women in both groups received luteal phase support in the form of vaginal progesterone, (Prontogest 400 mg Vaginal Pessaries, IBSA) twice a day, starting from the day after IUI and continued till the eighth week, if the pregnancy test was positive.Two weeks later, quantitative ßhCG was estimated to diagnose chemical pregnancy. However, TVS was performed 4 weeks after positive pregnancy test to confirm clinical pregnancy by the presence of gestational sac with fetal echoes and pulsation and to exclude ectopic pregnancy. All women enrolled in the study underwent the study protocol for three consecutive cycles unless got pregnant.
PURPOSE: A cosmetic composition containing Artemisiae Argyi Folium ethanol extract for preventing and treating brain cancer is provided to suppress brain cancer cell proliferation. CONSTITUTION: A composition for preventing and treating brain cancer contains Artemisiae Argyi Folium ethanol extract as an active ingredient, which is prepared by extracting Artemisiae Argyi Folium at 50 Deg. C. for 24 hours and concentrating at 45 Deg. C. and reduced pressure. The composition also contains pharmaceutically acceptable carriers or diluents. A functional food for preventing brain cancer contains the extract containing sitologically acceptable food additive as an active ingredient.
PURPOSE: A method for preparing gardenia fruit extract with enhanced anti-inflammatory activity is provided to change a material by an enzyme reaction using beta-glucosidase. CONSTITUTION: A gardenia fruit extract with enhanced anti-inflammatory activity is prepared by reacting beta-glucosidase to gardenia fruit extract at 20 unit/ml, pH 4.6, and 45°C for 24 hours. The gardenia fruit extract is obtained by adding a solvent to gardenia fruit and treating with microwaves at 90W for 5 minutes. The solvent is a mixture solvent of water-ethanol. A pharmaceutical composition for anti-inflammation contains gardenia fruit extract as an active ingredient. A health food for preventing and treating inflammation contains gardenia fruit extract as an active ingredient.
A polygenic risk score (PRS) combines the associations of multiple genetic variants that could be due to direct causal effects, indirect genetic effects, or other sources of familial confounding. We have developed new approaches to assess evidence for and against causation by using family data for pairs of relatives (Inference about Causation from Examination of FAmiliaL CONfounding [ICE FALCON]) or measures of family history (Inference about Causation from Examining Changes in Regression coefficients and Innovative STatistical AnaLyses [ICE CRISTAL]). Inference is made from the changes in regression coefficients of relatives' PRSs or PRS and family history before and after adjusting for each other. We applied these approaches to two breast cancer PRSs and multiple studies and found that (a) for breast cancer diagnosed at a young age, for example, <50 years, there was no evidence that the PRSs were causal, while (b) for breast cancer diagnosed at later ages, there was consistent evidence for causation explaining increasing amounts of the PRS-disease association. The genetic variants in the PRS might be in linkage disequilibrium with truly causal variants and not causal themselves. These PRSs cause minimal heritability of breast cancer at younger ages. There is also evidence for nongenetic factors shared by first-degree relatives that explain breast cancer familial aggregation. Familial associations are not necessarily due to genes, and genetic associations are not necessarily causal.
Childhood adversity is linked to psychological, behavioral, and physical health problems, including obesity and cardiometabolic disease. Epigenetic alterations are one pathway through which the effects of early life stress and adversity might persist into adulthood. Epigenetic mechanisms have also been proposed to explain why cardiometabolic health can vary greatly between individuals with similar Body Mass Index (BMIs). We evaluated two independent cross-sectional cohorts of adults without known medical illness, one of which explicitly recruited individuals with early life stress (ELS) and control participants (n = 195), and the other a general community sample (n = 477). In these cohorts, we examine associations between childhood adversity, epigenetic aging, and metabolic health. Childhood adversity was associated with increased GrimAge Acceleration (GAA) in both cohorts, both utilizing a dichotomous yes/no classification (both p < 0.01) as well as a continuous measure using the Childhood Trauma Questionnaire (CTQ) (both p < 0.05). Further investigation demonstrated that CTQ subscales for physical and sexual abuse (both p < 0.05) were associated with increased GAA in both cohorts, whereas physical and emotional neglect were not. In both cohorts, higher CTQ was also associated with higher BMI and increased insulin resistance (both p < 0.05). Finally, we demonstrate a moderating effect of BMI on the relationship between GAA and insulin resistance where GAA correlated with insulin resistance specifically at higher BMIs. These results, which were largely replicated between two independent cohorts, suggest that interactions between epigenetics, obesity, and metabolic health may be important mechanisms through which childhood adversity contributes to long-term physical and metabolic health effects.
Participants in the control arm will be provided with information about sources of wellbeing support they can access and will also be asked to fill out additional questionnaires at baseline, which will act as a control for time spent completing online activities. These measures are a Symptom Importance Rating Questionnaire, the Chalder Fatigue Questionnaire \[32\], Pittsburgh Sleep Quality Index \[33\], Snaith-Hamilton Pleasure Scale \[34\], Fatigue Associated with Depression Scale \[35\]. These will not be completed by the intervention group nor reported as main outcomes on the RCT itself, but will be used in separate observational projects.
The present invention relates to an adhesive composition for skin, an adhesive for skin, and an adhesive sheet for skin. The adhesive composition for skin herein is used for obtaining an adhesive for skin that can be readily coated and which has good aggregability. The adhesive for skin obtained using the adhesive composition for skin. The present invention also provides the adhesive sheet for skin. The adhesive composition for skin includes a radiation-curable resin and a reactive dilution that reacts with the radiation-curable resin. This adhesive composition for skin is capable of obtaining an adhesive for skin which can be coated easily and has good aggregability. Also provided are the adhesive for skin, obtained by irradiating radiation on the adhesive composition for skin; and the adhesive sheet for skin, having an adhesive layer formed from the adhesive composition for skin, provided upon a base material sheet.
OBJECTIVE: Following hypoxic-ischemic (HI) brain injury, neuronal cytoplasmic chloride concentration ([Cl-]i) increases, potentially contributing to depolarizing γ-aminobutyric acid (GABA) responses, onset of seizures, and the failure of antiepileptic drugs that target inhibitory chloride-permeable GABAA receptors. Post-HI seizures characteristically begin hours after injury, by which time substantial accumulation of [Cl-]i may have already occurred. In immature neurons, a major pathway for Cl- influx is the reversible Na+-K+-2Cl- cotransporter NKCC1.
METHODS: Spontaneous neuronal network, neuronal [Cl-]i, and GABA activity were determined in hippocampal preparations from neonatal Clomeleon and SuperClomeleon/DLX-cre mice to test whether blocking NKCC1 earlier after oxygen-glucose deprivation (OGD) injury would more effectively ameliorate the increase in [Cl-]i, ictallike epileptiform discharges (ILDs), and the failure of the GABAergic anticonvulsant phenobarbital.
RESULTS: In vitro, murine intact hippocampi were free of ILDs for 12 h after preparation. Transient OGD resulted in a gradual increase in [Cl-]i, depolarizing action of GABA, and facilitation of neuronal network activity. Spontaneous ILDs began 3-5 h after injury. Blocking NKCC1 with 2-10 μmol·L-1 bumetanide reduced [Cl-]i equally well when applied up to 10 h after injury. Whereas phenobarbital or bumetanide applied separately were less effective when applied later after injury, ILDs were successfully suppressed by the combination of phenobarbital and bumetanide regardless of the number of prior ILDs or delay in application.
SIGNIFICANCE: The present age-specific group studies demonstrate that after OGD, NKCC1 transport activity significantly contributes to progressive [Cl-]i accumulation, depolarizing action of GABA, and delayed onset of ILDs. In this neonatal model of neuronal injury and ILDs, earlier treatment with bumetanide alone more efficiently recovered control baseline [Cl-]i and depressed epileptiform discharges. However, there was no time dependency to the anti-ictal efficacy of the combination of phenobarbital and bumetanide. These in vitro results suggest that after perinatal injury, early pre-emptive treatment with phenobarbital plus bumetanide would be as efficacious as late treatment after seizures are manifest.
An adequate foot clearance height while stepping over an obstacle is important for safety in daily life. In the present study, we examined whether visual illusions affect foot clearance during a stepping-over action, and whether this is further influenced by gaze behavior. Twelve participants stepped over an obstacle placed four meters away under conditions of three different obstacle characteristics: white, horizontal, or vertical lines. We measured the participants' foot clearances during the step-over action and their gaze behavior during the approaching phase. Participants stepped significantly higher over the obstacles in the vertical lines (illusion) condition. The duration of gaze fixation on the obstacle positively correlated with increased foot clearance in the vertical condition, suggesting that the effect of the visual illusion on foot clearance was enhanced by prolonged gaze fixation. Conversely, prolonged fixation negatively correlated with foot clearance in the white (control) condition, implying that a cautious perception of an obstacle may contribute to efficient stepping-over action.